Shares of medical device maker Dexcom rose following the FDA's approval of its injectable continuous glucose-monitoring device, which could revolutionize the way patients manage diabetes. Dexcom CEO Andrew Rasdal did not comment about price and marketing strategies, but said patients might begin using the system within a week.

Related Summaries